Risk of secondary hypogammaglobulinaemia after Rituximab and Fludarabine in indolent non-Hodgkin lymphomas: A retrospective cohort study

• Published in: Leukemia research Vol. 39; no. 12; pp. 1382 - 1388
• Main Authors: De Angelis, Federico, Tosti, Maria Elena, Capria, Saveria, Russo, Eleonora, D’Elia, Gianna Maria, Annechini, Giorgia, Stefanizzi, Caterina, Foà, Robin, Pulsoni, Alessandro
• Format: Journal Article
• Language: English
• Published: England Elsevier Ltd 01.12.2015
• Subjects: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols - administration & dosage; Antineoplastic Combined Chemotherapy Protocols - adverse effects; Antineoplastic Combined Chemotherapy Protocols - therapeutic use; Bone Marrow - pathology; Cyclophosphamide - administration & dosage; Disease Susceptibility; Doxorubicin - administration & dosage; Female; Fludarabine; Hematology, Oncology and Palliative Medicine; Hematopoietic Stem Cell Transplantation; Humans; Hypogammaglobulinemia; IgG Deficiency - chemically induced; IgG Deficiency - epidemiology; Immunocompromised Host; Immunotherapy - adverse effects; Incidence; Kaplan-Meier Estimate; Lymphoma, Non-Hodgkin - drug therapy; Lymphoma, Non-Hodgkin - pathology; Lymphoma, Non-Hodgkin - therapy; Male; Middle Aged; Non-Hodgkin lymphoma; Pneumonia - etiology; Prednisone - administration & dosage; Proportional Hazards Models; Retrospective Studies; Rituximab; Rituximab - administration & dosage; Rituximab - adverse effects; Transplantation, Autologous; Vidarabine - administration & dosage; Vidarabine - adverse effects; Vidarabine - analogs & derivatives; Vincristine - administration & dosage; Young Adult; Non-Hodgkin lymphoma; Rituximab; Hypogammaglobulinemia; Fludarabine
• ISSN: 0145-2126; 1873-5835
• DOI: 10.1016/j.leukres.2015.10.013

Highlights • SH after chemo-immunotherapy is a risk factor for iNHL patients. • Our study investigated incidence and risk factors for SH, infective complications. • Incidence of SH was 2.2 × 1000 person-years. • Exposure to Fbs ± R and ASCT was statistically associated with SH incidence. • Exposure to CHOP ± R or CVP ± R was not a risk factor as well as Rituximab exposure.